AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.
Stocks · News reference
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Entered Strategic Drug Discovery Collaboration, Licensing Agreement With Insitro To Use Advanced AI Systems To Identify Novel Drug Targets, Develop Therapeutics For MASH, Cardiomyopathies
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.
Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60
BlackLine Honors Global Enterprise Leaders Transforming Financial Operations
BlackLine announced its 2026 Modern Accounting Awards, honoring six enterprise leaders—Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US Foods—for redefining financial operations through unified data architectures, intelligent automation, and agentic workflows. These organizations have eliminated tens of thousands of manual close hours and established continuous, audit-ready financial operations.